Argenx's study flop in Sjögren's overshadows a win in celiac disease
Argenx on Thursday reported one success and one setback in its autoimmune disease pipeline, sending its shares tumbling. The Belgian-Dutch pharma said it is shuttering a Phase 3 trial of its ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Sources: endpoints.news · statnews.com · biopharmadive.com
This story
This is one outlet's version. Read the fullest account.